Ignite Creation Date:
2024-10-26 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06551324
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-25
Brief Title:
A Study to Learn About the Investigational Medicine Called PF-06821497 Mevrometostat in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer MEVPRO-1
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A PHASE 3 RANDOMIZED OPEN-LABEL STUDY OF PF-06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO-1
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
MEVPRO-1
Brief Summary:
Pfizer MEVPRO-1 C2321014 is a randomized open-label multi-center clinical trial evaluating whether combining the study medicine PF-06821497 with enzalutamide is safe and effective compared to physicians choice of either second-line androgen receptor AR directed therapy with enzalutamide or docetaxel chemotherapy for treating metastatic castration-resistant prostate cancer mCRPC after progression on prior abiraterone acetate treatment
The primary objective of this clinical trial is to assess the radiographic progression free survival rPFS of the combination of PF-06821497 plus enzalutamide versus physicians choice of enzalutamide or docetaxel
The primary objective of this clinical trial is to assess the radiographic progression free survival rPFS of the combination of PF-06821497 plus enzalutamide versus physicians choice of enzalutamide or docetaxel
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None